Tonix Pharmaceuticals (TNXP) - 2024 Q3 - Quarterly Results

TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women Expect FDA decision in December 2024 on TNX-102 SL ...